Annals of nutrition & metabolism · 2026
Patient Acceptability of Partial Enteral Nutrition as a Concomitant Therapy to Adalimumab in Adults with Active Crohn's Disease: BIOPIC Trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fandinga Catarina, Clowe Jennifer, White Bernadette, Campbell Iona, Seenan John Paul, Brownson Emily, Milling Simon, Koutsos Athanasios, Ho Gwo-Tzer, Mowat Craig, Robertson Elaine, Gaya Daniel R, Kefayat Amirhosein, Din Shahida, MacDonald Jonathan, Gerasimidis Konstantinos
Аннотация
UNLABELLED: <p>Introduction: Partial enteral nutrition (PEN) is a dietary therapy for the management of Crohn's disease (CD). Although considered less restrictive than exclusive enteral nutrition, there are scarce data from patients with lived experience to support PEN. This study assessed dietary intake, the acceptability, and adherence to 50% PEN alongside treatment with adalimumab, for 6 weeks, in adults with active CD.
METHODS: Adherence to PEN was measured by three methods: an interview with a dietitian using an adherence questionnaire, dietary analysis from food diaries, and inventory from provided enteral nutrition formula and unused stock returned. Food diaries were also used to assess differences in intake between participants receiving 50% PEN (ADA + PEN group) and those who did not (ADA group).
RESULTS: Twenty-nine of 41 patients (71%) took the PEN volume prescribed every day for 6 weeks; 39 (95%) met the full PEN volume prescribed for 5 weeks or more. Fifty-nine percent reported no issues adhering to PEN, 11.5% felt too full, 10.5% reported social life constraints, and 5% taste fatigue. Most respondents would use PEN again to manage CD (93%). Food-diary analysis also showed high level of adherence (median [IQR] daily energy intake provided by PEN: 53% [49; 71.2]). The median (IQR) percentage of enteral feed used from the volume provided was 96% (88; 101). Participants in the ADA + PEN group modified the unrestricted portion of their diet, particularly dinners.
CONCLUSION: These results support the good acceptability rate of 50% PEN alongside treatment with adalimumab, emphasizing its potential of being a viable dietary treatment option for adults with CD. </p>.
METHODS: Adherence to PEN was measured by three methods: an interview with a dietitian using an adherence questionnaire, dietary analysis from food diaries, and inventory from provided enteral nutrition formula and unused stock returned. Food diaries were also used to assess differences in intake between participants receiving 50% PEN (ADA + PEN group) and those who did not (ADA group).
RESULTS: Twenty-nine of 41 patients (71%) took the PEN volume prescribed every day for 6 weeks; 39 (95%) met the full PEN volume prescribed for 5 weeks or more. Fifty-nine percent reported no issues adhering to PEN, 11.5% felt too full, 10.5% reported social life constraints, and 5% taste fatigue. Most respondents would use PEN again to manage CD (93%). Food-diary analysis also showed high level of adherence (median [IQR] daily energy intake provided by PEN: 53% [49; 71.2]). The median (IQR) percentage of enteral feed used from the volume provided was 96% (88; 101). Participants in the ADA + PEN group modified the unrestricted portion of their diet, particularly dinners.
CONCLUSION: These results support the good acceptability rate of 50% PEN alongside treatment with adalimumab, emphasizing its potential of being a viable dietary treatment option for adults with CD. </p>.